Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

Safety, Feasibility, and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer

(2016) Orhan Onder Eren et al.   AMERICAN JOURNAL OF THERAPEUTICS

Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction

(2015) Maarten J. Deenen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer

(2015) Jinwan Wang et al.   Gastric Cancer

Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study

(2015) Didier Meulendijks et al.   INVESTIGATIONAL NEW DRUGS

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

(2015) Lieke H J Simkens et al.   LANCET

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study

(2014) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation

(2014) Miao-zhen Qiu et al.   TUMOR BIOLOGY

Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis

(2014) Jianchun Gu et al.   TUMOR BIOLOGY

Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer susceptibility

(2014) Lei-Zhou Xia   WORLD JOURNAL OF GASTROENTEROLOGY

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

(2013) D W Miles et al.   BRITISH JOURNAL OF CANCER

Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer

(2013) Yoshikazu Uenosono et al.   CANCER

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

(2013) Jin Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells

(2012) Dick Pluim et al.   CYTOMETRY PART A

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Folate Intake along with Genetic Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase in Patients with Advanced Gastric Cancer

(2010) K. Shitara et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE